101094-05-7

Basic information

• Product Name: Modafinil Carboxylate Sulfone
• Synonyms: 2-[(Diphenylmethyl)sulfonyl]acetic Acid;Modafinil Carboxylate Sulfone;NSC 114215;ArModafinil IMpurity D
• CAS NO: 101094-05-7
• Molecular Formula: C₁₅H₁₄O₄S
• Molecular Weight: 290.33
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 101094-05-7.mol
• Article Data: 4

Chemical Properties

• Melting Point: 141-142 °C(Solv: benzene (71-43-2))
• Boiling Point: 552.9±50.0 °C(Predicted)
• Appearance: /
• Density: 1.330±0.06 g/cm3(Predicted)
• PKA: 2.41±0.10(Predicted)
• CAS DataBase Reference: Modafinil Carboxylate Sulfone(CAS DataBase Reference)
• NIST Chemistry Reference: Modafinil Carboxylate Sulfone(101094-05-7)
• EPA Substance Registry System: Modafinil Carboxylate Sulfone(101094-05-7)

Safety Data

• Hazardous Substances Data: 101094-05-7(Hazardous Substances Data)

Usage

Uses

Modafinil derivative as PAF antagonist

Upstream product

• 63547-22-8 (benzhydrylthio)acetic acid 
• 91-01-0 1,1-Diphenylmethanol 

Downstream Products

• 16003-65-9 Diphenylmethyl-dichlormethyl-sulfon 
• 16003-62-6 Diphenylmethyl-dibrommethyl-sulfon 

Relevant articles and documents

Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid

A process for the oxidation of thioethers to sulfoxides or sulfones or for the oxidation of sulfoxides to sulfones by treatment of thioethers or sulfoxides with an oxidizing amount of ε-phthalimidoperhexanoic acid is particularly useful for the preparation of compounds of industrial interest, in particular pharmaceuticals for human or veterinary use.

(2-Alkyl-3-pyridyl)methylpiperazine derivatives as PAF antagonists

The present invention relates to new (2-alkyl-3-pyridyl) methylpiperazine derivatives of general formula I: wherein R1, R2 and Z are as defined in Claim 1. The invention also relates to processes for their preparation and to pharmaceutical compositions containing them. These compounds are potent, orally active PAF antagonists and, consequently, they are useful in the treatment of the diseases in which this substance is involved.